ClinicalTrials.gg
CompletedNCT01911728Updated Jun 26, 2017

Drug-drug Interaction Study With MDV3100 and a Cocktail of Substrates

A Phase 1 interventional study of MDV3100 and Pioglitazone in Pharmacokinetics of MDV3100 and Castration Resistant Prostate Cancer (CRPC), sponsored by Astellas Pharma Europe B.V.. Completed at 2 sites in South Africa. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-06-26.

Sponsored by Astellas Pharma Europe B.V. (part of Astellas Pharma Inc) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years after the study started (first participant enrolled Jul 2011, registered Jul 2013).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
14
Allocation
Non-randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 125 studies testing enzalutamide in Prostatic Neoplasms — 17 open to participants now, 38 under way, 9 of them phase 3. enzalutamide · Prostatic Neoplasms.

Enrollment
108th of 125
14 · median 52
Started
2011
with 3 others
Phase 1
22 of 125
2 open now
Registered
16th of 125
by date
Lead sponsor
6 of 125
Astellas Pharma Europe B.V.

Among the 125 studies testing enzalutamide in Prostatic Neoplasms, this one is the 108th largest by enrollment, is one of 4 that started in 2011, is one of 22 in phase 1, and was the 16th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

17 of the 125 studies testing enzalutamide in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About enzalutamide

enzalutamide: first FDA approval 2012 (XTANDI), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies testing enzalutamide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

A drug-drug interaction study to investigate the potential pharmacokinetic interaction between MDV3100 and a cocktail of substrates for pioglitazone (CYP2C8 substrate), S-warfarin (CYP2C9 substrate), omeprazole (CYP2C19 substrate), and midazolam (CYP3A4 substrate).

03

Conditions studied

  • Pharmacokinetics of MDV3100
  • Castration Resistant Prostate Cancer (CRPC)

Browse trials for

Keywords

  • Drug-Drug Interaction
  • Phase 1
  • MDV3100
  • Xtandi
  • Enzalutamide
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features;
  • Ongoing androgen deprivation therapy with a gonadotropin releasing hormone (GnRH) analogue or orchiectomy (i.e., medical or surgical castration);
  • Progressive disease by prostate specific antigen (PSA) or imaging whether or not after chemotherapy in the setting of medical or surgical castration. Disease progression for study entry is defined as one or more of the following 3 criteria:

    • PSA progression defined by a minimum of 3 rising PSA levels with an interval of ≥1 week between each determination. The PSA value during the pre period should be ≥2 μg/L (2 ng/mL);
    • Soft tissue disease progression defined by the , version 1.1 (RECIST 1.1) for soft tissue disease (see Appendix A);
    • Bone disease progression defined by two or more new lesions on bone scan.

Exclusion criteria

Exclusion Criteria:

  • Confirmed CYP2C8, CYP2C9, or CYP2C19 poor metabolizer status based on genotyping analysis;
  • \< 1,500/μL, count \< 100,000/μL, and \< 5.6 mmol/L (9 g/dL) during the screening period (NOTE: patients may not have received any growth factors or blood transfusions within 7 days prior to the hematologic laboratory values obtained during the screening period);
  • Total > 1.5 times, or (ALT) or aspartate aminotransferase (AST) > 2 times the during the screening period;
  • Creatinine > 177 μmol/L (2 mg/dL) during the screening period;
  • Albumin \< 30 g/L (3.0 g/dL) during the screening period;
  • Treatment with androgen receptor antagonists (bicalutamide, flutamide, nilutamide), 5 α reductase inhibitors (finasteride, dutasteride), estrogens, or chemotherapy within 4 weeks prior to enrollment (Day 1 visit) or plans to initiate treatment with any of these treatments during the study;
  • Use of herbal products that may decrease PSA levels (e.g., saw palmetto) or systemic greater than the equivalent of 10 mg of prednisone/prednisolone per day within 4 weeks prior to enrollment (Day 1 visit) or plans to initiate treatment with any of these treatments during the study;
  • Structurally unstable bone lesions suggesting impending fracture;
  • History of seizure, including any febrile seizure, loss of consciousness, or transient ischemia attack within 12 months prior to enrollment (Day 1 visit), or any condition that may pre-dispose to seizure (e.g., prior stroke, brain arteriovenous malformation, head trauma with loss of consciousness requiring hospitalization)
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Multiple doses of MDV3100

    Multiple doses of MDV3100 and a single dose of pioglitazone and a single dose of cocktail containing -warfarin, omeprazole and midazolam

    Drug: MDV3100 · Drug: Pioglitazone · Drug: Warfarin · Drug: Omeprazole · Drug: Midazolam

Interventions

  • Oral

    Also known as: Xtandi, enzalutamide

  • Oral

  • DrugWarfarin

    Oral

  • DrugOmeprazole

    Oral

  • DrugMidazolam

    Oral

06

What researchers measure

Primary outcomes

  1. Assessment of the pharmacokinetic profile of pioglitazone (CYP2C8 substrate) in combination with MDV3100 PTM and MDV3100

    (Maximum concentration (observed))Cmax, (Area Under Curve from the time of dosing to the last measurable concentration)AUC0-t, (AUC extrapolated to infinity)AUC0-inf

    Time frame: Day 1 through Day 72 (75 times)

  2. Assessment of the pharmacokinetic profile of S-warfarin (CYP2C9 substrate) in combination with MDV3100 PTM and MDV3100

    (Maximum concentration (observed))Cmax, (Area Under Curve from the time of dosing to the last measurable concentration)AUC0-t, (AUC extrapolated to infinity)AUC0-inf

    Time frame: Day 1 through Day 72 (75 times)

  3. Assessment of the pharmacokinetic profile of omeprazole (CYP2C19 substrate) in combination with MDV3100 PTM and MDV3100

    (Maximum concentration (observed))Cmax, (Area Under Curve from the time of dosing to the last measurable concentration)AUC0-t, (AUC extrapolated to infinity)AUC0-inf

    Time frame: Day 1 through Day 72 (75 times)

  4. Assessment of the pharmacokinetic profile of midazolam (CYP3A4 substrate) in combination with MDV3100 PTM and MDV3100

    (Maximum concentration (observed))Cmax, (Area Under Curve from the time of dosing to the last measurable concentration)AUC0-t, (AUC extrapolated to infinity)AUC0-inf

    Time frame: Day 1 through Day 72 (75 times)

Secondary outcomes

  1. Assessment of the pharmacokinetic profile of substrates pioglitazone (CYP2C8 substrate), S-warfarin (CYP2C9 substrate), omeprazole (CYP2C19 substrate), and midazolam (CYP3A4 substrate) in combination with MDV3100 PTM and MDV3100

    (Time to attain Cmax)tmax (Apparent terminal elimination half-life)t1/2, (Apparent total body clearance after extravascular dosing)CL/F, (Apparent volume of distribution during the terminal phase after extravascular dosing)Vz/F, Cmax, AUC0-t, AUC0-inf, (Pre-dose plasma concentration)C0h, (Minimum concentration (observed))Cmin, (AUC between two consecutive doses at steady-state)AUCtau, (Peak-trough ratio)PTR

    Time frame: Day 1 through Day 72 (75 times)

  2. Monitoring of safety and tolerability through assessment of vital signs, Electrocardiogram (ECG) and clinical safety laboratory and, adverse events

    Time frame: Day 1 through Day 97

07

Study locations

2 sites
  • Parexel
    George, South Africa
  • Parexel/Qdot Pharma
    Port Elizabeth, South Africa
08

References and documents

Publications

  • Gibbons JA, de Vries M, Krauwinkel W, Ohtsu Y, Noukens J, van der Walt JS, Mol R, Mordenti J, Ouatas T. Pharmacokinetic Drug Interaction Studies with Enzalutamide. Clin Pharmacokinet. 2015 Oct;54(10):1057-69. doi: 10.1007/s40262-015-0283-1. PubMed 25929560 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2011 to primary completion in Feb 2012, 6 months.

Of 212 industry-sponsored phase 1 interventional studies under Prostatic Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's 6 months is below that.

Counting every sponsor, half of 456 studies reached it within 43 months; a quarter within 23 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2013
First posted
Jul 30, 2013
StartActual
Jul 25, 2011
Primary completionActual
Feb 21, 2012
CompletionActual
Feb 21, 2012
Last update
Jun 26, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01911728
Collaborators
Medivation, Inc.
Responsible party
Sponsor
First posted
Jul 30, 2013
Start date
Jul 25, 2011
Primary completion
Feb 21, 2012
Completion
Feb 21, 2012
Last update
Jun 26, 2017

Study contacts

Operation Senior Research Manager
study chair · Astellas Pharma Europe B.V.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enzalutamide

Start the discussion